Mechanism of Action
GLP-1 Receptor Activation
Semaglutide binds and activates GLP-1 receptors expressed on pancreatic beta cells, hypothalamic neurons, and peripheral tissues. Binding stimulates adenylyl cyclase, raising intracellular cAMP and triggering glucose-dependent insulin secretion. This glucose-dependency means insulin is only released when blood glucose is elevated, substantially reducing hypoglycemia risk compared to sulfonylureas.
Appetite and Weight Regulation
GLP-1 receptors in the hypothalamus (arcuate nucleus) and brainstem (area postrema) mediate satiety signaling. Semaglutide reduces appetite, increases fullness, and slows gastric emptying, collectively reducing caloric intake. Central mechanisms account for the majority of weight loss observed, distinguishing it from purely peripheral agents.
Cardiovascular and Metabolic Effects
SUSTAIN-6 and SELECT trials demonstrated significant reductions in major adverse cardiovascular events (MACE) in high-risk populations. Benefits include reduced systolic blood pressure, improved lipid profiles, decreased hepatic fat, and anti-inflammatory effects mediated partly via GLP-1 receptor activation on macrophages and endothelial cells.
Research Summary
Weight Management (STEP Trials)
Strong EvidenceThe STEP trial program (STEP 1-8) evaluated 2.4 mg weekly semaglutide for weight management. STEP 1 demonstrated mean 14.9% weight reduction vs 2.4% placebo over 68 weeks. STEP 3 (with lifestyle intervention) showed 16.0% reduction. SUSTAIN SELECT demonstrated 10.2% weight loss with cardiovascular benefit, establishing semaglutide as the most effective approved weight-loss pharmacotherapy to date.
Type 2 Diabetes (SUSTAIN Program)
Strong EvidenceSUSTAIN trials across diverse populations showed HbA1c reductions of 1.1-1.8% and fasting plasma glucose reductions of 2.2-4.1 mmol/L. Superior glycemic control vs comparators including sitagliptin, dulaglutide, and exenatide was consistently demonstrated. Oral semaglutide (PIONEER program) achieved comparable efficacy to injectable forms at optimal doses.
Cardiovascular Outcomes
Strong EvidenceSELECT trial (2023) enrolled 17,604 overweight/obese adults without diabetes and demonstrated 20% MACE reduction with semaglutide 2.4 mg vs placebo. This was the first dedicated cardiovascular outcomes trial for an obesity medication, significantly expanding approved indications.
Emerging Indications
Active ResearchOngoing trials explore semaglutide in NASH/MAFLD, Alzheimer's disease, Parkinson's disease, heart failure with preserved ejection fraction (STEP-HFpEF), alcohol use disorder, and obstructive sleep apnea. Early neurological data is particularly compelling, with GLP-1 receptors found throughout the brain.
Calculate your Semaglutide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Clinical Trial Data
| Phase | Trial | N | Duration | Key Outcome |
|---|---|---|---|---|
| Phase 3 | STEP-1 (obesity, no T2D) PMID:33567185 | 1,961 | 68 weeks | 14.9% mean body weight loss at 2.4 mg vs 2.4% placebo; 86.4% achieved >5% weight loss |
| Phase 3 | STEP-4 (withdrawal study) PMID:33625459 | 803 | 68 weeks | Weight regain 6.9% after switching to placebo; weight maintenance with continued semaglutide |
| Phase 3 | SELECT (CV outcomes, obese no T2D) PMID:37955268 | 17,604 | 33 months | 20% reduction in MACE in overweight/obese patients without T2D; landmark cardiovascular outcomes study |
| Phase 3 | SUSTAIN-6 (CV outcomes, T2D) PMID:28641428 | 3,297 | 104 weeks | 26% MACE reduction in high-risk T2D; FDA expanded label to include CV risk reduction |
| Phase 3 | FLOW (kidney outcomes) PMID:38717297 | 3,533 | 3.4 years | 24% reduction in kidney disease progression; 18% reduction in cardiovascular death; approved addition to label |
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Weight management | 0.25 mg/week x4 weeks, then 0.5 mg x4w, 1.0 mg x4w, 1.7 mg x4w, 2.4 mg maintenance | Weekly | Subcutaneous |
| Type 2 diabetes | 0.25 mg/week titrating to 1-2 mg/week | Weekly | Subcutaneous |
| Oral (T2D) | 3 mg/day x30 days, 7 mg x30 days, 14 mg maintenance | Daily fasting | Oral tablet |
Slow dose escalation minimizes GI side effects. Inject abdomen, thigh, or upper arm. Rotate sites.
Interactions
Safety Profile
Most common adverse effects are gastrointestinal: nausea (44%), vomiting (24%), diarrhea (30%), constipation (24%). These are dose-dependent and typically resolve after initial weeks. Serious but rare: pancreatitis, gallbladder disease, diabetic retinopathy progression (in rapidly improving glycemia), renal impairment from dehydration. Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2 (animal data showed thyroid C-cell tumors). Not recommended in pregnancy.
References
- [1]Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
- [2]Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.
- [3]Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.